Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
Animals
Antibodies, Neutralizing
/ blood
HIV Antibodies
/ blood
HIV Antigens
/ immunology
HIV Infections
/ immunology
HIV-1
/ immunology
Humans
Macaca mulatta
Male
Poxviridae
T-Lymphocytes
/ immunology
Vaccination
Vaccines, DNA
/ administration & dosage
Vaccinia virus
/ immunology
Viral Vaccines
/ immunology
Virus Replication
DNA vaccine
Gag-Pol-Nef
NYVAC
NYVAC-KC
T cell responses
antibody responses
gp140
human immunodeficiency virus
nonhuman primates
vaccine
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
received:
05
09
2018
accepted:
31
10
2018
pubmed:
16
11
2018
medline:
9
11
2019
entrez:
16
11
2018
Statut:
epublish
Résumé
The use of heterologous immunization regimens and improved vector systems has led to increases in immunogenicity of HIV-1 vaccine candidates in nonhuman primates. In order to resolve interrelations between different delivery modalities, three different poxvirus boost regimens were compared. Three groups of rhesus macaques were each primed with the same DNA vaccine encoding Gag, Pol, Nef, and gp140. The groups were then boosted with either the vaccinia virus strain NYVAC or a variant with improved replication competence in human cells, termed NYVAC-KC. The latter was administered either by scarification or intramuscularly. Finally, macaques were boosted with adjuvanted gp120 protein to enhance humoral responses. The regimen elicited very potent CD4
Identifiants
pubmed: 30429343
pii: JVI.01529-18
doi: 10.1128/JVI.01529-18
pmc: PMC6340047
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
HIV Antibodies
0
HIV Antigens
0
NYVAC vaccine
0
Vaccines, DNA
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : P30 AI064518
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI118581
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001414
Pays : United States
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
J Allergy Clin Immunol. 2010 Nov;126(5):898-907; quiz 908-9
pubmed: 21050940
J Immunol Methods. 2012 Dec 14;386(1-2):10-21
pubmed: 22955212
PLoS One. 2016 Feb 19;11(2):e0149364
pubmed: 26895072
Virology. 1992 May;188(1):217-32
pubmed: 1566575
Sci Transl Med. 2014 Mar 19;6(228):228ra39
pubmed: 24648342
Cytometry A. 2011 Aug;79(8):603-12
pubmed: 21735545
J Virol. 2015 Aug;89(16):8525-39
pubmed: 26041302
J Exp Med. 2008 Jan 21;205(1):63-77
pubmed: 18195071
Vaccine. 2008 Jun 13;26(25):3162-74
pubmed: 18502003
Expert Rev Vaccines. 2016 Aug;15(8):1015-27
pubmed: 26910195
Vaccine. 2011 Dec 9;30(1):78-94
pubmed: 22037204
J Infect Dis. 2017 May 1;215(9):1376-1385
pubmed: 28199679
PLoS One. 2016 Jul 21;11(7):e0157391
pubmed: 27442017
Sci Transl Med. 2015 Oct 21;7(310):310rv7
pubmed: 26491081
Nat Rev Genet. 2008 Oct;9(10):776-88
pubmed: 18781156
PLoS One. 2014 Feb 04;9(2):e87572
pubmed: 24504509
Science. 2013 May 24;340(6135):1237874
pubmed: 23704576
J Infect Dis. 1997 Apr;175(4):756-63
pubmed: 9086127
J Virol. 2009 Jun;83(11):5881-9
pubmed: 19321612
PLoS One. 2016 Apr 14;11(4):e0153484
pubmed: 27077384
J Virol. 2008 Dec;82(24):12449-63
pubmed: 18842730
J Virol. 2017 Apr 13;91(9):
pubmed: 28179536
Nat Rev Immunol. 2013 Jun;13(6):412-26
pubmed: 23681096
Nat Biotechnol. 2015 Jun;33(6):610-6
pubmed: 26006008
Immunol Rev. 2017 Jan;275(1):5-10
pubmed: 28133795
Nature. 2017 Mar 23;543(7646):559-563
pubmed: 28289286
Nat Med. 2016 Jul;22(7):762-70
pubmed: 27239761
J Virol. 2016 Mar 28;90(8):4133-4149
pubmed: 26865719
Curr Opin HIV AIDS. 2016 Nov;11(6):614-619
pubmed: 27636503
J Immunol. 2007 May 15;178(10):6596-603
pubmed: 17475891
Front Microbiol. 2016 Nov 02;7:1739
pubmed: 27853456
Immunity. 2017 Jun 20;46(6):1073-1088.e6
pubmed: 28636956
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
N Engl J Med. 2013 Nov 28;369(22):2083-92
pubmed: 24099601
J Immunol. 2016 Apr 1;196(7):3064-78
pubmed: 26944928
Science. 2015 Jul 10;349(6244):aac4223
pubmed: 26089353
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
J Infect Dis. 2005 Mar 1;191(5):654-65
pubmed: 15688278
Expert Rev Vaccines. 2016;15(3):349-65
pubmed: 26654478
J Virol. 2015 Jan 15;89(2):970-88
pubmed: 25355891
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5
pubmed: 23100539
Immunol Rev. 2017 Jan;275(1):245-261
pubmed: 28133811
Vaccine. 2008 Jun 13;26(25):3153-61
pubmed: 18502002
PLoS One. 2011;6(11):e25674
pubmed: 22096477
Hum Vaccin Immunother. 2015;11(1):27-36
pubmed: 25483512
Virology. 1990 Nov;179(1):276-86
pubmed: 2171207
Nat Med. 2000 Feb;6(2):207-10
pubmed: 10655111
J Virol. 2019 Jan 17;93(3):
pubmed: 30429340